# Shang‐Gin Wu

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/shang-gin-wu/

## Facts

| Field | Value |
| --- | --- |
| Citations | 3,536 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 31 |
| i10-index | 49 |
| Last Known Institution | National Taiwan University |
| OpenAlex ID | https://openalex.org/A5036843957 |
| ORCID iD | 0000-0001-8889-689X |
| Works | 132 |

## Researcher papers

- [Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer](https://scholariq.org/papers/management-of-acquired-resistance-to-egfr-tki-targeted-therapy-in-advanced-non/)
- [Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Mutations Is Associated with Poor Gefitinib Treatment Response](https://scholariq.org/papers/lung-cancer-with-epidermal-growth-factor-receptor-exon-20-mutations-is/)
- [The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients](https://scholariq.org/papers/the-mechanism-of-acquired-resistance-to-irreversible-egfr-tyrosine-kinase/)
- [Survival of lung adenocarcinoma patients with malignant pleural effusion](https://scholariq.org/papers/survival-of-lung-adenocarcinoma-patients-with-malignant-pleural-effusion/)
- [EML4-ALK Translocation Predicts Better Outcome in Lung Adenocarcinoma Patients with Wild-Type EGFR](https://scholariq.org/papers/eml4-alk-translocation-predicts-better-outcome-in-lung-adenocarcinoma-patients/)
- [IL-8 confers resistance to EGFR inhibitors by inducing stem cell properties in lung cancer](https://scholariq.org/papers/il-8-confers-resistance-to-egfr-inhibitors-by-inducing-stem-cell-properties-in/)
- [Clinical and the Prognostic Characteristics of Lung Adenocarcinoma Patients with ROS1 Fusion in Comparison with Other Driver Mutations in East Asian Populations](https://scholariq.org/papers/clinical-and-the-prognostic-characteristics-of-lung-adenocarcinoma-patients-with/)
- [Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion–Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations](https://scholariq.org/papers/efficacy-of-pemetrexed-based-chemotherapy-in-patients-with-ros1-fusion-positive/)
- [Good Response to Gefitinib in Lung Adenocarcinoma Harboring Coexisting EML4-ALK Fusion Gene and EGFR Mutation](https://scholariq.org/papers/good-response-to-gefitinib-in-lung-adenocarcinoma-harboring-coexisting-eml4-alk/)
- [Good Response to Gefitinib in Lung Adenocarcinoma of Complex Epidermal Growth Factor Receptor (<i>EGFR</i>) Mutations with the Classical Mutation Pattern](https://scholariq.org/papers/good-response-to-gefitinib-in-lung-adenocarcinoma-of-complex-epidermal-growth/)
- [Complex EGFR mutations with secondary T790M mutation confer shorter osimertinib progression-free survival and overall survival in advanced non-small cell lung cancer](https://scholariq.org/papers/complex-egfr-mutations-with-secondary-t790m-mutation-confer-shorter-osimertinib/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Radiomics and Machine Learning in Medical Imaging](https://scholariq.org/topics/radiomics-and-machine-learning-in-medical-imaging/)
- [RNA modifications and cancer](https://scholariq.org/topics/rna-modifications-and-cancer/)

## Researcher university

- [National Taiwan University](https://scholariq.org/institutions/national-taiwan-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.